CNTRL Antibody / Centriolin / CEP110, 100 ug

CNTRL antibody detects Centriolin (also known as CEP110 or Centriole-associated protein CNTRL), a large coiled-coil protein that localizes to centrosomes and the midbody, where it regulates cytokinesis and cell cycle progression. Encoded by the CNTRL gene on chromosome 9q33.2, this protein functions as a structural scaffold coordinating membrane trafficking, microtubule organization, and abscission during late mitosis. CNTRL interacts with both centrosomal and Golgi-derived vesicle components, linking cytokinetic machinery with secretory pathways required for cell division completion.

Centriolin contains multiple coiled-coil domains and leucine zipper motifs that mediate self-association and recruitment of other midbody proteins, including exocyst complex components (EXOC6 and EXOC8) and SNARE regulators. During mitosis, CNTRL localizes to the midbody ring structure where it anchors vesicles essential for the final abscission step separating daughter cells. Loss of CNTRL disrupts cytokinesis, leading to multinucleation and cell cycle arrest. The protein also contributes to centrosome cohesion and Golgi organization during interphase, maintaining proper microtubule anchoring and intracellular transport.

The CNTRL antibody is widely used in cell biology and cancer research to study centrosome dynamics, cytokinesis, and vesicle trafficking. In immunofluorescence microscopy, CNTRL staining reveals punctate centrosomal and midbody localization, while western blot analysis identifies a high molecular weight band of approximately 230 kilodaltons. Because defects in CNTRL function are associated with abnormal cell division and chromosomal instability, this antibody is valuable for examining mitotic control and tumorigenesis. CNTRL dysregulation has been reported in several cancers, including glioblastoma and ovarian carcinoma, where centrosome amplification and cytokinetic failure contribute to genomic instability.

Beyond its role in mitosis, CNTRL participates in cilia formation and signaling. It anchors specific vesicles involved in ciliogenesis, linking basal bodies to the Golgi apparatus. The CNTRL antibody enables detection of this dual localization pattern and supports mechanistic studies into centrosome-related diseases (centrosomopathies). NSJ Bioreagents provides this antibody validated for its applications, ensuring specific detection of Centriolin across human and model systems. By targeting this key structural protein, researchers can investigate the molecular framework underlying cytokinesis, centrosome integrity, and vesicular organization.